UniProtKB/Swiss-Prot Q9UGN4: Variant p.Arg111Gln

CMRF35-like molecule 8
Gene: CD300A
Feedback?

Variant information Variant position:

111 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Arginine (R) to Glutamine (Q) at position 111 (R111Q, p.Arg111Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs2272111 [ dbSNP | Ensembl ]

Sequence information Variant position:

111 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

299 The length of the canonical sequence.
Location on the sequence:

ENLTEEDAGTYWCGVDTPWL R DFHDPVVEVEVSVFPASTSM The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ENLTEEDAGTYWCGVDTPWLRDF--HDPVVEVEVSVFPASTSM

Mouse                         ESLTLEDADTYMCAVDISLFDGSLGFDKYFKIELSVVPSED

Rat                           QNLTLEDAGTYMCAVDIPLIDHS------FKVELSVVPGNI

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	18 – 299	CMRF35-like molecule 8
Topological domain	18 – 180	Extracellular
Domain	19 – 123	Ig-like V-type
Glycosylation	92 – 92	N-linked (GlcNAc...) asparagine
Alternative sequence	14 – 209	Missing. In isoform 3.
Alternative sequence	14 – 126	Missing. In isoform 2 and isoform 4.

Literature citations
IRC1 isoforms.
Cantoni C.; Biassoni R.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3); VARIANT GLN-111; Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility.
Speckman R.A.; Wright Daw J.A.; Helms C.; Duan S.; Cao L.; Taillon-Miller P.; Kwok P.Y.; Menter A.; Bowcock A.M.;
Hum. Genet. 112:34-41(2003)
Cited for: VARIANT GLN-111;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.